Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Kewalramani cast the moment as an “opportunity to change the paradigm of acute pain management and establish a new standard of care.” Still, Journavx faces some hurdles in winning over ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

Dean Maglaris, CEO of Cytogel Pharma Cytogel is inspired by broader progress & committed to innovating in the field of pain management, s ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about prostate cancer awareness and ...